| Previous Close | 1.70 |
| Volume | 96,541 |
| Price / Sales | 6.93 |
| Price / Book | 0.420 |
| 52 Weeks Range |
| Operating Margin (TTM) | -493.01% |
| Diluted EPS (TTM) | -1.41 |
| Quarterly Revenue Growth (YOY) | 37.10% |
| Total Debt/Equity (MRQ) | 8.17% |
| Current Ratio (MRQ) | 19.34 |
| Operating Cash Flow (TTM) | -47.07 M |
| Levered Free Cash Flow (TTM) | -31.36 M |
| Return on Assets (TTM) | -15.54% |
| Return on Equity (TTM) | -24.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Seer, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.6 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.22 |
Select this tab to load the latest available analysis.
|
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.10% |
| % Held by Institutions | 67.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aju Ib Investment Co., Ltd. | 31 Mar 2026 | 816,375 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |